Early life exposure to potent AHR agonists on gut microbiota and its potential effects on metabolic health later in life.
Merck KGaA stays positive on CDMO arm’s future despite first-quarter slump
Merck KGaA’s revenue from its CDMO arm dropped in the first quarter due to customer destocking, but it still expects business to pick up in